New hope for kids with hard-to-treat leukemia: combo therapy trial opens
NCT ID NCT05645718
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of chemotherapy drugs (mini-Hyper-CVD) plus three targeted drugs (rituximab, inotuzumab ozogamicin, and blinatumomab) in children and young adults whose B-cell acute lymphocytic leukemia has come back or not responded to treatment. The goal is to see if this approach can control the disease. About 27 participants will be enrolled at M.D. Anderson Cancer Center.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New dashboard aims to make leukemia trials more inclusive
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot